{"id":3345,"date":"2022-03-21T08:50:16","date_gmt":"2022-03-21T08:50:16","guid":{"rendered":"https:\/\/newsnetworks.co.in\/en\/2022\/03\/21\/kilitch-drugs-starts-rs-100-crore-new-facility-expansion-plan\/"},"modified":"2022-03-21T08:50:16","modified_gmt":"2022-03-21T08:50:16","slug":"kilitch-drugs-starts-rs-100-crore-new-facility-expansion-plan","status":"publish","type":"post","link":"https:\/\/newsnetworks.co.in\/en\/2022\/03\/21\/kilitch-drugs-starts-rs-100-crore-new-facility-expansion-plan\/","title":{"rendered":"Kilitch Drugs Starts Rs. 100 Crore New Facility Expansion Plan"},"content":{"rendered":"
\"\"<\/div>\n

Mr. Mukund Mehta, Chairman & Managing Director of Kilitch Drugs<\/p>\n

New Delhi (India), March 21<\/strong>: Kilitch Drugs India Limited is a Leading MSME multinational manufacturer of Injectables in India and Ethiopia. Kilitch has purchased 15 Acres land parcel in Village: Maldev, Taluka: Pen, on Pen \u2013 Khopoli Highway, Maharashtra, as the beginning of its expansion plan.<\/p>\n

The land bought by the company will be used for establishing a state-of-the-art greenfield pharma manufacturing complex. The company plans to set up 4-6 manufacturing units in different therapeutics categories to cater to the growing demands in Domestic and Exports markets. The expansion will be in a similar line of products like Injectables and other Biotech products. The project envisaged is futuristic and shall have maximum recognition of the world\u2019s leading regulatory authorities.<\/p>\n

Commenting on this\u00a0Mr. Mukund Mehta, Chairman & Managing Director of Kilitch Drugs, said<\/strong>, \u201cWe are on a growth trajectory and demand for our products is increasing. This expansion will help us to fuel our growth plan. This will be an ultra-modern facility, and the capex requirement for this facility will be in tune of approx. Rs. 100 Crore.<\/p>\n

We are planning to fund the capex mainly through internal accruals, and it will be in a phased manner. We are looking for a horizon of 2 years to commence commercial production of Phase I. Once the total expansion is complete, it will generate a Revenue opportunity of approx. Rs. 500 Crore.\u201d<\/p>\n

Established in 1978, Kilitch Drug (India) is a successful pharmaceutical solution company. The company has a major focus in the African region and have a strong foothold across key African countries, with 350 products in 26 African countries.<\/p>\n

The Company has a manufacturing plant located in Mumbai with a dedicated dry powder section and small volume liquid ampoules and vials. In 2018 the Company started a greenfield project in Ethiopia for Cephalosporins Injectables. The Company\u2019s manufacturing plants are certified by WHO, WHO GMP, ISO 9001, ISO 13845 etc.<\/p>\n

The Company\u2019s strong clientele includes Intas, Mankind, Indoco Remedies, and a few.<\/p>\n

For FY21 the Company has achieved Total Revenue of Rs. 74.21 crore with PAT of Rs. 6.16 crore.<\/p>\n","protected":false},"excerpt":{"rendered":"

Mr. Mukund Mehta, Chairman & Managing Director of Kilitch Drugs New Delhi (India), March 21: Kilitch Drugs India Limited is a Leading MSME multinational manufacturer of Injectables in India and Ethiopia. Kilitch has purchased 15 Acres land parcel in Village: Maldev, Taluka: Pen, on Pen \u2013 Khopoli Highway, Maharashtra, as the beginning of its expansion […]<\/p>\n","protected":false},"author":1,"featured_media":3346,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[35],"class_list":["post-3345","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-news-networks"],"_links":{"self":[{"href":"https:\/\/newsnetworks.co.in\/en\/wp-json\/wp\/v2\/posts\/3345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsnetworks.co.in\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsnetworks.co.in\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsnetworks.co.in\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsnetworks.co.in\/en\/wp-json\/wp\/v2\/comments?post=3345"}],"version-history":[{"count":0,"href":"https:\/\/newsnetworks.co.in\/en\/wp-json\/wp\/v2\/posts\/3345\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsnetworks.co.in\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/newsnetworks.co.in\/en\/wp-json\/wp\/v2\/media?parent=3345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsnetworks.co.in\/en\/wp-json\/wp\/v2\/categories?post=3345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsnetworks.co.in\/en\/wp-json\/wp\/v2\/tags?post=3345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}